To explore the role of TNFR2 in tumor-enhancing inflammation and immune evasion, and to evaluate specific therapeutic strategies targeting the TNF-TNFR2 pathway, including monoclonal antibodies and bispecific antibodies.
Key Findings:
TNFR1 mediates cytotoxic signaling, while TNFR2 promotes tumor-enhancing inflammation and immunosuppression, highlighting the need for targeted therapies.
TNFR2 is predominantly expressed on regulatory T cells, myeloid-derived suppressor cells, and cancer-associated fibroblasts, contributing to immune evasion.
Targeting TNFR2 may help overcome resistance to immune checkpoint blockade therapies, potentially improving patient outcomes.
Interpretation:
The TNF-TNFR2 pathway plays a critical role in immune evasion within the tumor microenvironment, suggesting that selective targeting of TNFR2 could significantly enhance the efficacy of cancer immunotherapies.
Limitations:
Potential on-target toxicity associated with TNFR2 targeting could impact patient safety and treatment adherence.
Challenges in patient stratification for targeted therapies may limit the effectiveness of TNFR2-targeted approaches.
Context-dependent biology of TNFR2 complicates therapeutic approaches, necessitating careful consideration in treatment design.
Conclusion:
Targeting TNFR2 presents a promising strategy to address immune resistance in tumors and improve outcomes for patients undergoing immunotherapy.
